Prosecution Insights
Last updated: November 20, 2026
Application No. 17/932,798

COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72

Final Rejection §112
Filed
Sep 16, 2022
Priority
Mar 18, 2020 — provisional 62/991,403 +2 more
Examiner
MCLEOD, AFRICA MHAIRIE
Art Unit
1635
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Scribe Therapeutics Inc.
OA Round
3 (Final)
59%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
34 granted / 58 resolved
-1.4% vs TC avg
Strong +58% interview lift
Without
With
+58.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
35 currently pending
Career history
106
Total Applications
across all art units

Statute-Specific Performance

§101
5.5%
-34.5% vs TC avg
§103
26.3%
-13.7% vs TC avg
§102
18.4%
-21.6% vs TC avg
§112
30.9%
-9.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 58 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s response filed 08/18/2026 has been received and considered entered. This is a response to amendments and arguments filed 08/18/2026. Election/Restrictions Applicant’s election without traverse of a gNA targeting sequence of SEQ ID NO:321 and of an NLS sequence of SEQ ID NO:167 in the reply filed on 10/02/2025 was acknowledged in the non-final action mailed 12/23/2025. Claims Status Claims 3-10, 12-27, 30-40, 42-46, 48-51, 53-64, 66-78, 80, 82-83, 85-92, 94, 96-111, 113-114, 116-146, 148-192 is/are cancelled. Claims 1-2, 11, 28-29, 41, 47, 52, 65, 79, 81, 84, 93, 95, 112, 115, 147, 193 is/are currently pending. Claims 1-2, 11, 28-29, 41, 46-47, 52, 65, 79, 81, 84, 93, 95, 112, 115, 147, 193 is/are under examination. Claim Rejections - 35 USC § 112 112(a): The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Written Description: Claims 1-2, 11, 28-29, 41, 47, 52, 65, 79, 81, 84, 93, 95, 112, 115, 147, 193 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection is maintained. To satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. See, e.g., Moba, B.V, v. Diamond Automation, Inc., 325 F.3d 1306, 1319, 66 USPQ2d 1429, 1438 (Fed. Cir. 2003); Vas-Cath, Inc. v. Mahurkar, 935 F.2d at 1563, 19 USPQ2d at 1116. Possession may be shown in a variety of ways including description of an actual reduction to practice, or by showing that the invention was "ready for patenting" such as by the disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the applicant was in possession of the claimed invention. See, e.g., Pfaff v. Wells Eiees., Inc., 525 U.S. 55, 68, 119 S.Ct. 304, 312, 48 USPQ2d 1641,1647 (1998); Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406; Amgen, Inc. v. Chugai Pharm., 927 F. 2d 1200, 1206, 18 USPQ2d 1016, 1021 (Fed. Cir. 1991) (one must define a compound by "whatever characteristics sufficiently distinguish it”). According to the MPEP § 2163, "The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice (see i)(A) above), reduction to drawings (see i)(B) above), or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus (see i)(C) above). See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. See AbbVie Deutsch land GmbH & Co., KG v. Janssen Biotech, Inc., 759 F.3d 1285, 1300, 111 USPQ2d 1780, 1790 (Fed. Cir. 2014) (Claims directed to a functionally defined genus of antibodies were not supported by a disclosure that "only describe[d] one type of structurally similar antibodies" that "are not representative of the full variety or scope of the genus.")." Claims 1 and 79 recite CasX variant proteins comprising sequences at least 95% identical to SEQ ID NO:138. This creates an enormous genus of proteins. Claims 1 and 79 recite gNAs comprising target sequences “complementary to a target nucleic acid sequence comprised in a chromosome 9 open reading frame 72 (C9orf72) gene or in an expression control region of the C9orf72 gene” (lines 7-8). Claim 11 recites a gNA comprising a sequence at least 85% identical to SEQ ID NOs:309-343, 363-2100, or 2295-21835, creating an enormous genus of gNA sequences. In analyzing whether the written description requirement is met for genus claims, it is first determined whether a representative number of species have been described by their complete structure. In the instant case, the only species of variant CasX proteins described comprise SEQ ID NOs:72, 94, 113, 130-138, 141-144, 239, 277, or 280 (paragraph [0201]); the only species of gNA targeting sequences are SEQ ID NOs:309-343, 363-2100, and 2295-21835 (paragraph [0101]). While the genera encompass a large number of variant proteins and gNA sequences that have the same activity (RNA-guided DNA-targeting and cleaving activity of variant CasX proteins, CasX- and DNA-binding activity of variant gNA sequences) and the genera encompass large numbers of variants and molecules that have different structures, the specification does not describe the complete structures of representative numbers of species of the large genera of variant CasX proteins and variant gNA sequences. Next, then, it is determined whether a representative number of species have been sufficiently described by other relevant identifying characteristics (i.e., other than amino acid or nucleotide sequence, or chemical modification), specific features and functional attributes that would distinguish different members of the claimed genera. In the instant case, the only other identifying characteristic of the variant CasX proteins is that they “exhibit at least one improved characteristic compared to the reference CasX protein” (paragraph [0172]), wherein the at least one improved characteristic can be, but is not limited to, “improved folding of the variant, improved binding affinity to the gNA, improved binding affinity to the target DNA, altered binding affinity to one or more PAM sequences, improved unwinding of the target DNA, increased activity, improved editing efficiency, improved editing specificity, increased activity of the nuclease, increased target strand loading for double strand cleavage, decreased target strand loading for single strand nicking, decreased off-target cleavage, improved binding of the non-target strand of DNA, improved protein stability, improved protein:gNA complex stability, improved protein solubility, improved protein:gNA complex solubility, improved protein yield, improved protein expression, and improved fusion characteristics” (paragraph [0175]). The only other identifying characteristic of the variant gNAs is that they “have one or more improved functions or characteristics, or add one or more new functions when the variant gNA is compared to a reference gRNA”, including, but not limited to, “improved stability; improved solubility; improved transcription of the gNA; improved resistance to nuclease activity; increased folding rate of the gNA; decreased side product formation during folding; increased productive folding; improved binding affinity to a CasX protein; improved binding affinity to a target DNA when complexed with a CasX protein; improved gene editing when complexed with a CasX protein; improved specificity of editing when complexed with a CasX protein; and improved ability to utilize a greater spectrum of one or more PAM sequences, including ATC, CTC, GTC, or TTC, in the editing of target DNA when complexed with a CasX protein” (paragraph [0111]). Such functional limitations cannot be identifying characteristics for the claimed diverse genera of molecules since by Applicant’s definition of variant CasX proteins and gNAs, all members of the claimed genera will have these characteristics. Further, no identifying characteristics of the modified CasX proteins and gNAs are disclosed. The inventions of claims 2, 28-29, 41, 46-47, 52, 65, 81, 84, 93, 95, 112, 115, 147, 193 require the use of the inventions of claims 1, 11, and 79 and are likewise rejected under 35 U.S.C. 112(a) as failing to comply with the written description requirement. Enablement: The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 193 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification does not reasonably provide enablement for a method of treating a disease associated with C9orf72 by targeting a gNA to a sequence comprised in a C9orf72 gene or C9orf72 gene expression control region. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. This rejection is maintained. The breadth of the claims: With respect to claim breadth, the standard under 35 U.S.C. §112, first paragraph, entails the determination of what the claims recite and what the claims mean as a whole. As such, the broadest reasonable interpretation of the claimed methods is that they encompass methods of treating a disorder associated with C9orf72 (see claim 193), by administering a CasX-gNA system targeting a C9orf72 gene sequence. A skilled artisan would not know how to use the method with a reasonable expectation of success based solely on what is disclosed in the specification. The amount of direction provided by the inventor and the level of predictability in the art: The specification teaches that the intended use of the claimed methods of modifying a C9orf72 gene in vivo is in a method of treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (paragraphs [0003]-[0006]). The art at the time of filing provided enabling guidance for expected therapeutic efficacy of Cas9-gRNA systems in the treatment of C9orf72-related ALS and FTD, wherein the gRNA targets the promoter region controlling expression of C9orf72 (Krishnan, 2020), or wherein the gRNAs target two sequences within the C9orf72 gene and flanking the GC-rich expansion region (Pribadi, 2016). However, the prior art did not provide enabling guidance for methods of treating C9orf72-related diseases ALS and FTD using gRNA targeting any other sequence within the C9orf72 gene sequence or a C9orf72 expression control region, or any sequence not in the C9orf72 gene or expression control region. The specification as filed does not provide guidance that overcomes this unpredictability within the art. The existence of working examples: What is enabled by the working examples is narrow in comparison to the breadth of the claims: The specification discloses working examples in vitro wherein the CasX-gNA systems are shown to be capable of targeting and cleaving a C9orf72 gene sequence (paragraphs [0533]-[0548]). The specification provides prophetic examples of methods of treating animal models of C9orf72-related neurodegeneration; however, the disclosure teaches gNA targeting the promoter region, Exon 1, and Intron 1, including HRE, of C9orf72 (see Fig. 22). The quantity of experimentation needed to make or use the invention: The standard of an enabling disclosure is not the ability to make and test if the invention works but one of the ability to make and use with a reasonable expectation of success. A patent is granted for a completed invention, not the general suggestion of an idea (MPEP 2164.03 and Chiron Corp. v. Genentech Inc., 363 F.3d 1247, 1254, 70 USPQ2d 1321, 1325-26 (Fed. Cir. 2004). The instant specification is not enabling because one cannot follow the guidance presented therein, or within the art at the time of filing, and practice the claimed method without first making a substantial inventive contribution. Given that the nature of the invention encompasses in vivo treatment of any C9orf72-related disease using a gNA targeting any sequence anywhere within any nucleic acid comprising a C9orf72 gene (including all of human chromosome 9), a person having ordinary skill in the art would have to perform multiple further experiments, in human clinical trials or in animal models that are predictive of treatment, using a representative number of gNAs targeting a representative number of sequences comprised in any nucleic acid comprising a C9orf72 gene, in order to demonstrate the invention could be used with a reasonable expectation of success. The amount of experimentation required for enabling guidance, commensurate in scope with what is claimed, goes beyond what is considered ‘routine' within the art, and constitutes undue further experimentation in order to use the method with a reasonable expectation of successfully treating any CNS disorder or neurodegenerative disease. Therefore, Claim 193 is rejected under 35 U.S.C. 112, first paragraph, for failing to meet the enablement requirement. Response to Arguments Applicant's arguments filed 08/18/2026 have been fully considered but they are not fully persuasive. Regarding the written description rejection: On page 12, Applicant argues that “the Specification discloses numerous specific CasX variant proteins, including those set forth in SEQ ID NOs: 72, 94, 113, 130-138, 141-144, 239, 277, and 280…These sequences span the breadth of the claimed genus and are representative of the CasX variant proteins encompassed by the percent identity threshold.” Applicant further argues that “the Specification identifies specific structural domains and mutations that confer the improved characteristics recited in the claims. In particular, the Specification describes the NTSB domain, the helical I domain, the helical II domain, the OBD domain, and the RuvC domain, and further describes specific amino acid substitutions within these domains that contribute to improved DNA unwinding, target strand loading, and editing efficiency.” Paragraph [0160] of the specification describes that the NTSBD “is a domain not previously found in any Cas proteins”; therefore, any art describing the structure-function relationship of domains of other known Cas proteins would not be able to reasonably predict the functional consequence of mutating any given amino acid residue in the NTSBD. While the specification describes that an NTSBD may have a sequence of amino acids 101-191 of SEQ ID NO:1 or 103-192 of SEQ ID NO:2, this does not describe which amino acid residues may be changed or which must be preserved to maintain or enhance certain protein functions. While the specification does provide a list of some possible amino acid residue alterations (see for example, paragraph [0184]), these are recited as non-limiting (“In some embodiments”). As CasX varies substantially in sequence from other CRISPR endonucleases, such as Cas9, evidence of CasX structure-function understanding which would lend such predictability to variant CasX proteins must be provided in the disclosure or from the prior art and made of record. Since the disclosure does not provide a description of which amino acid residues may be altered or must be conserved in order to preserve or enhance particular features or functions of the CasX variant proteins, an artisan would not be able to rely on the disclosure or on the prior art to determine which amino acid residue alterations do or do not confer the functional enhancements recited in the claims or specification, nor which amino acid residues must be conserved in order to preserve functionality of the CasX variant proteins. Regarding gNA sequence identity thresholds, Applicant argues that “at least 85%” sequence identity threshold is narrowed sufficiently to be “within the predictable range of structure-function for CRPSR guide nucleic acids” (page 13). However, as described by Anderson (2015), Cas9 systems are known in the art to tolerate up to 2 mismatches, which would coincide with a 90% sequence identity threshold for a guide RNA targeting sequence of 20-24 nucleic acids—and the instant guide RNA sequences fall within the range of 20-24 nucleic acids in length. Increasing the sequence identity threshold for the gNAs to 90% sequence identity would be sufficient to overcome the written description rejection regarding the gNA percent sequence identity. Regarding the enablement rejection: Applicant argues that, regarding the enablement rejection of claim 193, methods of treating diseases associated with C9orf72 are enabled. Applicant argues that in vitro working examples disclosed in the specification enable CasX/gNA targeting and modification of C9orf72; that prophetic examples in the specification describe different methods of targeting segments of C9orf72 known to be associated with ALS and FTD; that, as conceded by the Examiner previously, in vivo delivery methods for CRISPR systems, specifically AAV, were enabled in the art; and that prior art references Krishnan and Pribadi enable methods of treating ALS by targeting C9orf72 hexanucleotide repeats with a CRISPR system. While Applicants would be enabled for methods of delivering to organisms in vivo the claimed CRISPR system targeting C9orf72 and the expression control region of C9orf72, enablement for delivery alone is not sufficient to show enablement for methods of treating a disease. For the latter, sufficient evidence must be provided by the Applicants or present in the prior art to enable an artisan to reasonably assume the disease can be treated in an affected organism using the claimed method. In vitro methods are not sufficient to provide such enablement if the cell models used in the in vitro methods are not predictive of therapeutic success in vivo. Pribadi teaches on page 12 that the cells used were good models of fetal neurons, but not good models of adult, diseased brains, and that the results were not entirely as anticipated. This would indicate to an artisan significant unpredictability in the capacity of a CRISPR system targeting the C9orf72 hexanucleotide repeat to treat diseases associated with C9orf72. Krishnan likewise teaches use of a CRISPR system targeting the C9orf72 hexanucleotide repeat in vitro in iPSC-derived cells, and thus also does not describe the use of such a CRISPR system in a model representative of the diseased nervous system. While both Pribadi and Krishnan discuss the possible therapeutic uses of their respective CRISPR applications, their in vitro cellular models are not predictive of treatment success or feasibility in human patients. Therefore, an artisan would not be able to reasonably assume that a disease associated with C9orf72 would be able to be treated using the claimed method of claim 193. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AFRICA M MCLEOD whose telephone number is (703)756-1907. The examiner can normally be reached Mon-Fri 9:00AM-6:00PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. For those applications where applicant wishes to communicate with the examiner via Internet communications, e.g., email or video conferencing tools, the following is a sample authorization form which may be used by applicant: "Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with the undersigned and practitioners in accordance with 37 CFR 1.33 and 37 CFR 1.34 concerning any subject matter of this application by video conferencing, instant messaging, or electronic mail. I understand that a copy of these communications will be made of record in the application file." To facilitate processing of the internet communication authorization or withdraw of authorization, the Office strongly encourages use of Form PTO/SB/439, available at www.uspto.gov/patent/patents-forms. The form may be filed via EFS-Web using the document description Internet Communications Authorized or Internet Communications Authorization Withdrawn to facilitate processing. See MPEP 502.03(II). Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AFRICA M MCLEOD/ Examiner, Art Unit 1635 /KIMBERLY CHONG/ Primary Examiner, Art Unit 1636
Read full office action

Prosecution Timeline

Sep 16, 2022
Application Filed
Dec 23, 2025
Non-Final Rejection mailed — §112
Apr 14, 2026
Response Filed
May 19, 2026
Non-Final Rejection mailed — §112
Aug 18, 2026
Response Filed
Oct 29, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799486
OLIGONUCLEOTIDES FOR PRNP MODULATION
1y 1m to grant Granted Nov 17, 2026
Patent 12774456
Compositions and Methods for Gene Editing
4y 3m to grant Granted Oct 27, 2026
Patent 12774458
BASE EDITING ENZYMES
3y 7m to grant Granted Oct 27, 2026
Patent 12767959
NUCLEOBASE EDITORS HAVING REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING SAME TO MODIFY A NUCLEOBASE TARGET SEQUENCE
5y 2m to grant Granted Oct 20, 2026
Patent 12767939
COMPOSITIONS AND METHODS FOR GENE EDITING
4y 6m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+58.1%)
3y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 58 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month